🇺🇸 Onabotulinum Toxin A in United States

10 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 22 April 2025 – 22 April 2026
• Total reports: 10

Most-reported reactions

1. Blood Glucose Decreased — 1 report (10%)
2. Blood Glucose Increased — 1 report (10%)
3. Bronchial Secretion Retention — 1 report (10%)
4. Cardiac Failure Congestive — 1 report (10%)
5. Cold Sweat — 1 report (10%)
6. Drug Ineffective For Unapproved Indication — 1 report (10%)
7. Economic Problem — 1 report (10%)
8. Flushing — 1 report (10%)
9. Hyperhidrosis — 1 report (10%)
10. Liver Function Test Abnormal — 1 report (10%)

Source database →

Frequently asked questions

Is Onabotulinum Toxin A approved in United States?

Onabotulinum Toxin A does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for Onabotulinum Toxin A in United States?

Walter Reed National Military Medical Center is the originator. The local marketing authorisation holder may differ — check the official source linked above.